Maternal plasma and breastmilk viral loads are associated with HIV-1-specific cellular immune responses among HIV-1-exposed, uninfected infants in Kenya

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 509-519

  Liu, A Y ^a   Lohman Payne, B ^a   Chung, M H ^a   Kiarie, J ^b   Kinuthia, J ^a   Slyker, J ^a   Richardson, B ^a,b,c   Lehman, D ^c   Farquhar, C ^a   John Stewart, G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c USA   (United States)

Author keywords

HIV 1 EU; Interferon gamma; Paediatric immunity

Indexed keywords

CD4 ANTIGEN; GAG PROTEIN; LAMIVUDINE; NEVIRAPINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAMMA INTERFERON;

ADULT; ARTICLE; BREAST MILK; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; KENYA; MAJOR CLINICAL STUDY; MATERNAL PLASMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; VIRUS LOAD; BLOOD; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; NEWBORN; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INFANT; INFANT, NEWBORN; INTERFERON-GAMMA; KENYA; MILK, HUMAN; PREGNANCY; VIRAL LOAD; YOUNG ADULT;

EID: 84929508000     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12599     Document Type: Article

References (47)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2010; 2010. Available at: http://www.unaids.org/globalreport/Global_report.html.
2. Nduati R, John G, Mbori-Ngacha D et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167-74.
3. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
4. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.
5. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332:201-8.
6. Hay CM, Ruhl DJ, Basgoz NO et al. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol 1999; 73:5509-19.
7. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-72.
8. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-50.
9. Musey LK, Krieger JN, Hughes JP, Schacker TW, Corey L, McElrath MJ. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 1999; 180:278-84.
10. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for anti-retroviral therapeutics. Ann Intern Med 2001; 134:978-96.
11. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann Intern Med 2001; 134:761-76.
12. Wasik TJ, Wierzbicki A, Whiteman VE, Trinchieri G, Lischner HW, Kozbor D. Association between HIV-specific T helper responses and CTL activities in pediatric AIDS. Eur J Immunol 2000; 30:117-27.
13. Kalams SA, Buchbinder SP, Rosenberg ES et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999; 73:6715-20.
14. Musey LK, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74.
15. Jennes W, Vuylsteke B, Borget MY et al. HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire. J Infect Dis 2004; 189:602-10.
16. Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102:1758-65.
17. Fowke KR, Kaul R, Rosenthal KL et al. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol 2000; 78:586-95.
18. Kebba A, Kaleebu P, Rowland S et al. Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis 2004; 189:1705-13.
19. Perez CL, Hasselrot K, Bratt G, Broliden K, Karlsson AC. Induction of systemic HIV-1-specific cellular immune responses by oral exposure in the uninfected partner of discordant couples. AIDS 2010; 24:969-74.
20. Schenal M, Lo Caputo S, Fasano F et al. Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. AIDS 2005; 19:653-61.
21. Kuhn L, Coutsoudis A, Moodley D et al. T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS 2001; 15:1-9.
22. De Maria A, Cirillo C, Moretta L. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J Infect Dis 1994; 170:1296-9.
23. Rowland-Jones S, Nixon D, Aldhous MC et al. HIV-specific cytotoxic T cell activity in an HIV exposed but uninfected infant. Lancet 1993; 341:860-1.
24. Borkowsky W, Krasinski K, Moore T, Papaevangelou V. Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children. AIDS Res Hum Retroviruses 1990; 6:673-8.
25. Clerici M, Sison AV, Berzofsky JA et al. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS 1993; 7:1427-33.
26. Kuhn L, Meddows-Taylor S, Gray G et al. Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course anti-retroviral treatment for prevention of maternal-infant transmission. Clin Exp Immunol 2001; 123:443-50.
27. Wasik TJ, Bratosiewicz J, Wierzbicki A et al. Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J Immunol 1999; 162:4355-64.
28. Aldhous MC, Watret KC, Mok JY, Bird AG, Froebel KS. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection. Clin Exp Immunol 1994; 97:61-7.
29. John-Stewart GC, Mbori-Ngacha D, Lohman-Payne B et al. HIV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis 2009; 199:889-98.
30. Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol 1995; 154:433-43.
31. McFarland EJ, Harding PA, Luckey D, Conway B, Young RK, Kuritzkes DR. High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection. J Infect Dis 1994; 170:766-74.
32. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, John-Stewart GC. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS 2005; 19:1415-22.
33. Chung MH, Kiarie JN, Richardson BA et al. Highly active anti-retroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 RNA: a phase II randomized clinical trial. Antivir Ther 2008; 13:799-807.
34. Lehman DA, Chung MH, John-Stewart GC et al. HIV-1 persists in breast milk cells despite anti-retroviral treatment to prevent mother-to-child transmission. AIDS 2008; 22:1475-85.
35. Emery S, Bodrug S, Richardson BA et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 2000; 38:2688-95.
36. Panteleeff DD, John G, Nduati R et al. Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol 1999; 37:350-3.
37. Shapiro RL, Ndung'u T, Lockman S et al. Highly active anti-retroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 2005; 192:713-9.
38. Farquhar C, Lohman-Payne B, Overbaugh J et al. Breast milk HIV-1 RNA levels and female sex are associated with HIV-1-specific CD8+ T-cell responses in HIV-1-exposed, uninfected infants in Kenya. J Infect Dis 2011; 204:1806-10.
39. Kaul R, Rowland-Jones SL, Kimani J et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001; 79:3-13.
40. Willberg CB, McConnell JJ, Eriksson EM et al. Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLOS Pathog 2008; 4:e1000185.
41. Schramm DB, Meddows-Taylor S, Gray GE, Kuhn L, Tiemessen CT. Low maternal viral loads and reduced granulocyte-macrophage colony-stimulating factor levels characterize exposed, uninfected infants who develop protective human immunodeficiency virus type 1-specific responses. Clin Vaccine Immunol 2007; 14:348-54.
42. Kebba A, Kaleebu P, Serwanga J et al. HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans. AIDS Res Hum Retroviruses 2004; 20:67-75.
43. McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008; 372:1894-905.
44. Garcia F, Bernaldo de Quiros JC, Gomez CE et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine 2011; 29:8309-16.
45. Churchyard GJ, Morgan C, Adams E et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLOS ONE 2011; 6:e21225.
46. Genesca M. Characterization of an effective CTL response against HIV and SIV infections. J Biomed Biotechnol 2011; 2011:103924.
47. Bunders MJ, van der Loos CM, Klarenbeek PL et al. Memory CD4+CCR5+ T cells are abundantly present in the gut of newborn infants to facilitate mother-to child transmission of HIV-1. Blood 2012; 120:4383-90.